Literature DB >> 30380558

Results of Fabry Disease Screening in Male Pre-End Stage Renal Disease Patients with Unknown Etiology Found Through the Platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center.

Cheng-Jui Lin1,2, Yin-Hsiu Chien3, Thung-S Lai4, Hong-Mou Shih1, Yi-Chou Chen1, Chi-Feng Pan1, Han-Hsiang Chen1,2, Wuh-Liang Hwu3, Chih-Jen Wu5,6,7.   

Abstract

BACKGROUND/AIMS: Fabry disease (FD), a rare x-lined genetic disorder is a cause of renal deterioration. The phenotype of FD is highly variable and nonspecific, and correct diagnosis has always been delayed. We aimed to explore the prevalence and clinical presentation of FD in this high-risk male population in a Northern Taiwan medical center.
METHODS: This is the first study to survey the incidence of FD in this high-risk population through the platform of a chronic kidney disease (CKD) education program in Asia. A total of 1,012 male patients with unknown CKD causes were screened using an assay of alpha-galactosidase A activity (α-Gal A) by dried blood spots (DBS). A final GLA gene analysis was also done for those with low enzyme activity.
RESULTS: We identified two new patients with classic FD and four patients with late-onset FD. One novel GLA mutation with c.413 G>A was found in one classic FD patient (index 5). The prevalence of FD is about 0.59 % (6 in 1,012) in the high-risk population group with CKD. The clinical symptoms of FD patients are nonspecific except in those with various degrees of renal failure. Those patients' correct diagnosis was delayed, taking years and even decades. Three patients received enzyme replacement therapy and one started regular hemodialysis due to persistent renal function deterioration. Another two patients were found from family screening through a new index. In addition, a false negative result occurred in one patient who was proved to have FD by his kidney pathology as determined by this screening.
CONCLUSION: FD is not such as rare a disease and its prevalence is greater in this high-risk male population. Clinicians need to be aware that FD should be included in the differential diagnosis in CKD with unknown etiology.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Chronic kidney disease; Fabry disease; High-risk screening

Mesh:

Substances:

Year:  2018        PMID: 30380558     DOI: 10.1159/000494678

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  7 in total

1.  Identification and functional characterization of the first deep intronic GLA mutation (IVS4+1326C>T) causing renal variant of Fabry disease.

Authors:  Xuantong Dai; Xue Zong; Xiaoxia Pan; Wei Lu; Geng-Ru Jiang; Fujun Lin
Journal:  Orphanet J Rare Dis       Date:  2022-06-20       Impact factor: 4.303

Review 2.  The benefits and challenges of family genetic testing in rare genetic diseases-lessons from Fabry disease.

Authors:  Dominique P Germain; Sergey Moiseev; Fernando Suárez-Obando; Faisal Al Ismaili; Huda Al Khawaja; Gheona Altarescu; Fellype C Barreto; Farid Haddoum; Fatemeh Hadipour; Irina Maksimova; Mirelle Kramis; Sheela Nampoothiri; Khanh Ngoc Nguyen; Dau-Ming Niu; Juan Politei; Long-Sun Ro; Dung Vu Chi; Nan Chen; Sergey Kutsev
Journal:  Mol Genet Genomic Med       Date:  2021-04-09       Impact factor: 2.183

Review 3.  Deficiency in the Screening Process of Fabry Disease: Analysis of Chronic Kidney Patients Not on Dialysis.

Authors:  Yuri Battaglia; Fulvio Fiorini; Cristiano Azzini; Pasquale Esposito; Alessandro De Vito; Antonio Granata; Alda Storari; Renzo Mignani
Journal:  Front Med (Lausanne)       Date:  2021-02-09

4.  The Benefits of Family Screening in Rare Diseases: Genetic Testing Reveals 165 New Cases of Fabry Disease among At-Risk Family Members of 83 Index Patients.

Authors:  Sergey Moiseev; Ekaterina Tao; Alexey Moiseev; Nikolay Bulanov; Ekaterina Filatova; Victor Fomin; Dominique P Germain
Journal:  Genes (Basel)       Date:  2022-09-09       Impact factor: 4.141

5.  High Prevalence of Late-Onset Fabry Cardiomyopathy in a Cohort of 499 Non-Selective Patients with Left Ventricular Hypertrophy: The Asian Fabry Cardiomyopathy High-Risk Screening Study (ASIAN-FAME).

Authors:  Yiting Fan; Tsz-Ngai Chan; Josie T Y Chow; Kevin K H Kam; Wai-Kin Chi; Joseph Y S Chan; Erik Fung; Mabel M P Tong; Jeffery K T Wong; Paul C L Choi; David K H Chan; Bun Sheng; Alex Pui-Wai Lee
Journal:  J Clin Med       Date:  2021-05-17       Impact factor: 4.241

6.  Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy.

Authors:  Chandu Sadasivan; Josie T Y Chow; Bun Sheng; David K H Chan; Yiting Fan; Paul C L Choi; Jeffrey K T Wong; Mabel M B Tong; Tsz-Ngai Chan; Erik Fung; Kevin K H Kam; Joseph Y S Chan; Wai-Kin Chi; D Ian Paterson; Manohara Senaratne; Neil Brass; Gavin Y Oudit; Alex P W Lee
Journal:  PLoS One       Date:  2020-09-28       Impact factor: 3.240

7.  Screening of Fabry disease in patients with chronic kidney disease in Japan.

Authors:  Akiko Nagata; Makoto Nasu; Yusuke Kaida; Yosuke Nakayama; Yuka Kurokawa; Nao Nakamura; Ryo Shibata; Takuma Hazama; Takahiro Tsukimura; Tadayasu Togawa; Seiji Saito; Hitoshi Sakuraba; Kei Fukami
Journal:  Nephrol Dial Transplant       Date:  2021-12-31       Impact factor: 5.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.